Financial health
- Operating income covered interest expense -41251.8× in the latest year.
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
PROK Financials PROKIDNEY CORP.
5 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $893000 | -$69M | 0.0% | -18477.8% | -$135M | — | $109M |
| 2024 | $76000 | -$61M | 0.0% | -241678.9% | -$156M | — | $99M |
| 2023 | $0 | -$35M | — | — | -$124M | — | $61M |
| 2022 | $0 | — | — | — | -$79M | — | $490M |
| 2021 | — | -$2M | — | — | -$6M | — | $21M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $226000 | -$20M | 0.0% | -19881.9% | -$45M | — | $102M |
| Dec '25 | $225000 | -$19M | 0.0% | -20164.9% | -$38M | — | $109M |
| Sep '25 | $217000 | -$16M | 0.0% | -17759.9% | -$32M | — | $95M |
| Jun '25 | $221000 | -$17M | 0.0% | -17967.9% | -$35M | — | $85M |
| Mar '25 | $230000 | -$17M | 0.0% | -17994.8% | -$31M | — | $98M |
| Dec '24 | $76000 | -$21M | 0.0% | -67856.6% | -$50M | — | $99M |
| Sep '24 | $0 | -$18M | — | — | -$32M | — | $108M |
| Jun '24 | $0 | -$13M | — | — | -$39M | — | $215M |
| Mar '24 | $0 | -$9M | — | — | -$36M | — | $84M |
| Dec '23 | — | -$6M | — | — | -$27M | — | $61M |
| Sep '23 | — | -$11M | — | — | -$52M | — | $191M |
| Jun '23 | — | -$9M | — | — | -$19M | — | $244M |
| Mar '23 | — | -$10M | — | — | -$27M | — | $272M |
| Dec '22 | — | -$25M | — | — | -$16M | — | $490M |
| Sep '22 | — | -$30M | — | — | -$23M | — | $506M |
| Jun '22 | — | -$2M | — | — | -$23M | — | — |
| Mar '22 | — | -$4M | — | — | -$16M | — | — |
| Dec '21 | — | -$2M | — | — | -$613638 | — | $21M |
| Sep '21 | — | -$252490 | — | — | — | — | $542304 |
| Jun '21 | — | -$5325 | — | — | — | — | $223538 |
Valuation over time
How the market has priced PROK against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 1368.5× (Dec '24) to 117.2× (Jun '26).
P/S
Frequently asked questions
Is PROK growing its revenue and profit?
See the revenue and net-income charts above for PROKIDNEY CORP.'s multi-year trend.
How much debt does PROK have?
As of FY2025, PROKIDNEY CORP. reported — of total debt against $109M of cash; operating income covered interest expense -41251.8×.
What is PROK's profit margin?
In FY2025, gross margin was —, operating margin -18477.8%, and net margin -7725.2%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.